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Background: Chemotherapy induced nausea and vomiting (CINV) remains a major problem that seriously impairs
the quality of life (QoL) in cancer patients receiving chemotherapy regimens. Complementary medicines, including
homeopathy, are used by many patients with cancer, usually alongside with conventional treatment. A randomized,
placebo-controlled Phase III study was conducted to evaluate the efficacy of a complex homeopathic
medicine, Cocculine, in the control of CINV in non-metastatic breast cancer patients treated by standard
chemotherapy regimens.
Methods: Chemotherapy-naïve patients with non-metastatic breast cancer scheduled to receive 6 cycles of
chemotherapy including at least three initial cycles of FAC 50, FEC 100 or TAC were randomized to receive standard
anti-emetic treatment plus either a complex homeopathic remedy (Cocculine, registered in France for treatment of
nausea and travel sickness) or the matching placebo (NCT00409071 clinicaltrials.gov). The primary endpoint was
nausea score measured after the 1st chemotherapy course using the FLIE questionnaire (Functional Living Index for
Emesis) with 5-day recall. Secondary endpoints were: vomiting measured by the FLIE score, nausea and vomiting
measured by patient self-evaluation (EVA) and investigator recording (NCI-CTC AE V3.0) and treatment compliance.
Results: From September 2005 to January 2008, 431 patients were randomized: 214 to Cocculine (C) and 217 to
placebo (P). Patient characteristics were well-balanced between the 2 arms. Overall, compliance to study treatments
was excellent and similar between the 2 arms. A total of 205 patients (50.9%; 103 patients in the placebo and 102
in the homeopathy arms) had nausea FLIE scores > 6 indicative of no impact of nausea on quality of life during the
1st chemotherapy course. There was no difference between the 2 arms when primary endpoint analysis was
performed by chemotherapy stratum; or in the subgroup of patients with susceptibility to nausea and vomiting
before inclusion. In addition, nausea, vomiting and global emesis FLIE scores were not statistically different at any
time between the two study arms. The frequencies of severe (Grade ≥ 2) nausea and vomiting were low in our
study (nausea: P: 17.6% vs C: 15.7%, p=0.62; vomiting: P: 10.8% vs C: 12.0%, p=0.72 during the first course).
(Continued on next page)* Correspondence: isabelle.ray-coquard@lyon.unicancer.fr
1Centre Léon Bérard, 28 rue Laennec, Lyon Cedex 08 69373, France
9Centre Léon Bérard, 28 rue Laennec, Lyon 69008, France
Full list of author information is available at the end of the article
© 2012 Pérol et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Pérol et al. BMC Cancer 2012, 12:603 Page 2 of 9
http://www.biomedcentral.com/1471-2407/12/603(Continued from previous page)
Conclusion: This double-blinded, placebo-controlled, randomised Phase III study showed that adding a complex
homeopathic medicine (Cocculine) to standard anti-emetic prophylaxis does not improve the control of CINV in
early breast cancer patients.
Keywords: Early breast cancer, Adjuvant chemotherapy, Homeopathy, Nausea and vomiting, Quality of lifeBackground
Chemotherapy induced nausea and vomiting (CINV) are
among the most severe and feared collateral effects
of chemotherapy [1-3] associated with a significant
deterioration in quality of life (QoL) and patients’ ability
to carry out daily activities [4,5]. Poor QoL can influence
the patient’s willingness to continue with and suc-
cessfully complete cancer treatment. Therefore, it is
essential to prevent and treat these side effects optimal-
ly to maximize QoL and to encourage patient
compliance [5,6].
Over the past few years, selective serotonin type 3 re-
ceptor (5-HT3) antagonists and the neurokinin-1 (NK-1)
antagonist aprepitant have substantially improved the
management of acute CINV (occurring within 24 hours
of chemotherapy) and to a lesser extent delayed
CINV (occurring more than 24 hours post-chemother-
apy) [7-12]. Nevertheless, 75% percent of patients with
nausea and 50% of those with vomiting reported a nega-
tive impact on the performance of daily living activities
when queried with the Functional Living Index–Emesis
(FLIE) questionnaire despite modern prophylactic anti-
emetic treatment [13]. To date, CINV remains a signifi-
cant problem contributing to patient withdrawal from
potentially curative chemotherapy [5,8-10].
In an attempt to alleviate collateral effects of cancer
therapies, complementary and alternative medicines are
increasingly used by cancer patients [14,15]. In an Euro-
pean survey, 35.9% of cancer patients have reported
using some form of complementary or alternative medi-
cines (CAM) to reduce cancer treatment-related adverse
events (AEs) [15]. Homeopathy was in the top five of the
most commonly used CAM in 7 out of 14 European
countries [15]. Overall, homeopathic approaches are
used by cancer patients to alleviate their pain resulting
from the disease itself or from conventional anti-cancer
treatment [15]. Homeopathic medicines efficacy have
been studied in the treatment of adverse effects of radio-
therapy and chemotherapy in breast cancer patients.
However, large, randomized, placebo-controlled trials
with powered statistical analysis are needed to generate
evidence-based data on the value of complementary
medicine.
Different homeopathic practices coexist: the “classical”
or “individualised” homeopathy using single homeopathic
medicine that is prescribed according to the individual’scondition and history, (ii) the “clinical” homeopathy that
uses the same homeopathic medicine for a group of
patients with the same disease and (iii) the “complex”
homeopathy that uses more than one homeopathic medi-
cine, in a fixed combination or concurrently, for a particu-
lar condition. Cocculine is a homeopathic medicinal
product registered in France for treatment of nausea and
travel sickness composed of 4 homeopathic components
(Cocculus indicus 4 CH, Tabacum 4 CH, Nux vomica 4
CH, Petroleum 4 CH produced by Boiron, France, accord-
ing to European Pharmacopoeia). A recent study has
demonstrated that Cocculine has a potential interest for
the management of CINV with a 30% reduction of nausea
under Cocculine treatment compared to placebo in breast
cancer patients treated by chemotherapy (overall n=80: in-
cidence of nausea 61.5% in Cocculine arm versus 87.5%
with placebo [16]). The main objective of the present
study was to evaluate if this complex homoepathic medi-
cine can improve the control of CINV in non-metastatic
breast cancer patients in a large, randomized, multicenter
Phase III trial.Methods
Patients
Eligible women patients were chemotherapy-naive
adults with non metastatic, histologically proven breast
cancer and an Eastern Cooperative Oncology Group
performance status (ECOG PS) of ≤ 2, scheduled to re-
ceive 6 cycles of standard adjuvant chemotherapy. The
first 3 cycles were required to be FAC50 (5-Fluoruracil
500 mg/m [2] + adriamycin [doxorubicin] 50 mg/m [2] +
cyclophosphamide 500 mg/m [2]), FEC100 (5-Fluoruracil
500 mg/m [2] + epirubicin 100 mg/m [2] + cyclophosphamide
500 mg/m [2]) or TAC (Taxotere [Docetaxel] 75 mg/m
[2] + adriamycine 50 mg/m [2] + cyclophosphamide
500 mg/m [2]). Patients with previous malignancies (ex-
cept those in complete remission for more than 5 years),
contraindications to corticoids or 5-HT3 receptor
antagonists, or prior treatment with Cocculine or other
anti-emetics within the previous 15 days were ineligible.
Pregnant or lactating patients, those who could not be
followed up for social, geographical, familial or psycho-
logical reasons or unavailability by phone were also
excluded. The protocol was approved by a French eth-
ical committee (CPP Sud Est IV) and registered with
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have signed an inform consent form before study entry.
Randomisation and blinding
Randomisation was conducted centrally via a computer-
generated system, using permuted blocks of four
patients (the Jadad/Oxford score was ≥ 3/5). Patients
were stratified by participating centre and type of
chemotherapy regimen (FAC50 or FEC100 versus TAC).
Allocation list was generated by the study statistician be-
fore the beginning of the study. Investigators asked the
coordinating center by fax for a treatment allocation
number. Both investigator and patient remained blind to
the assignment of individuals to either active treatment
or placebo throughout the study.
Study treatments
The trial used a randomized, multicenter, double blind
phase III design in which patients were randomly
assigned to receive placebo or Cocculine (CocculineW,
Boiron- France) plus standard anti emetic treatment.
Cocculine is a complex of four active elements incorpo-
rated in the same tablets. The placebo tablets were iden-
tical seemingly in the active tablets (packaging, colour,
shape. . .). The placebo tablets were inert and contained
only (Saccharose (75%), lactose (24%), and Magnesium
stearate (1%)) without any homeopathic components. All
patients received a box containing six * two blister packs
of ten tablets corresponding to the treatment number
allocated at randomisation (Cocculine or matching pla-
cebo). Patients had to return boxes and tablet blisters to
the investigator at the end of treatment. Two tablets
were to be taken in the evening before chemotherapy, 6
on the day of chemotherapy and 4 tablets the next day
(see Table 1). A standard anti-emetic treatment was
given to patient: ondansetron 8 mg (or granisetron 3 mg
in case of intolerance to ondansetron) and methylpredi-
nosolone 80 mg. While this trial was being conducted,
consensus guidelines were updated to recommend the
use of a three-drug combination of steroids plus 5-HT3
receptor antagonist plus the NK-1 receptor antagonistTable 1 Study flow-chart (per chemotherapy cycle)
Day-1 Day 1
Tablets of Cocculine or placebo Evening Morning Noon Evening
Antiemetic treatment 2 2 2 2
Chemotherapy P1 (TAC) S2 + M3 S4 + P1




Po: per os; IV: intraverious; P: Prednisolone; M: Methyprednisolone; S: Ondansetron.
1: 60 mg po (TAC only); 2: 8 mg IV; 3: 60mg IV; 4: 8 mg po; *: all patients; **: on patieaprepitant [7,17]. At the time of patient enrolment, apre-
pitant was not recommended and so was not used dur-
ing the study. The study flow chart is presented in
Table 1.
Assessment
The primary objective was to evaluate the efficacy of
Cocculine versus Placebo when added to conventional
corticoid plus setron prophylaxis in the control of
chemotherapy-induced nausea during the 1st cycle of
chemotherapy. The secondary objectives were to evalu-
ate the efficacy of Cocculine during the 2nd and 3rd
cycles, the contribution of Cocculine in the treatment of
nausea and vomiting, and compliance to Cocculine
treatment. To evaluate the impact of homeopathy rem-
edy in the control of CINV based on patients’ assess-
ment: a self-assessment booklet composed of the FLIE
questionnaire [18,19] and a specific diary were given to
patients. In addition, CINV were also evaluated based
on investigators’ assessment using the CTCAE V3.0
grading scale.
The self–administered FLIE questionnaire is composed
of two dimensions (nausea and vomiting) each with 9
items. Each item consists of a horizontal Visual Ana-
logical Scale (VAS) of 100 mm graduated from 1 (a lot)
to 7 (not at all). The first question in each domain asks
the patient to rate how much nausea or vomiting she
has experienced over the past 5 days. The remaining
eight questions specifically address the impact of CINV
on daily activities (i.e. physical abilities, social and emo-
tional function) [18,19]. No or minimal impact on daily
life was defined as an average FLIE item score > 6.
Patients completed the FLIE questionnaire on Day 6 of
the first 3 chemotherapy cycles.
Patients were also provided with a daily diary to rec-
ord i) intake of study drug ii) the occurrence and inten-
sity of nausea during the first 24 hours and over days 2
to 5 following chemotherapy and the number of vomit-
ing episodes, and iii) use of any rescue antiemetic medi-
cations. All patients were contacted by telephone on the
day before the start of chemotherapy and (if theyDay 2 Day3 Day4 Day 5 Day 6
Morning Noon Evening Morning
2 2
S4 + P1 S4 + P1 S4 + P1
X**
X
X X X X
nts’ request.
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the diary and FLIE questionnaire had been completed
accurately. In addition, the incidence and severity of AEs
(NCI-CTCAE v3.0, ctep.cancer.gov/protocolDevelopment/
electronic. . ./docs/ctcaev3.pdf) including nausea and
vomiting were recorded by the investigator at the end
of each chemotherapy cycle. Data were collected until
either the cessation of chemotherapy or the administra-
tion of a maximum of 6 cycles of treatment.Statistical analysis
The study was powered to detect a 0.5 point difference
between treatment arms in the FLIE nausea score after
the 1st CT cycle. Accepting a two-sided type I error of
5% and a type II error of 15%, 198 patients were
required per group. The statistical analysis was per-
formed by intent-to-treat.
The primary endpoint was the mean of 9 first FLIE
items (at least 5 out of 9 items had to be completed).
Scores were compared between the two arms using the
non parametric Mann–Whitney U test. The number of
patients with a mean score > 6 versus the number of
patients with a mean score ≤ 6 were compared using
Fisher’s exact test.
The emesis score after the 1st, 2nd and 3rd chemother-
apy cycles and the nausea score after the 2nd and 3rd
chemotherapy cycles were calculated in order to evaluate
the efficacy of Cocculine over the first 3 CT cycles.
Vomiting frequency reported on the VAS during the
1st, 2nd and 3rd CT courses was compared between the
two arms by a Pearson’s chi-square test (or a Fisher’s
exact test, if appropriate).217 assigned to Placebo group
217 received Placebo as allocated
15 patients were non evaluable
15questionnaires not received
431 patients were included betw
January 2008 and underw
202 included in primary endpoint analysis 
per ITT
Figure 1 CONSORT diagram.Compliance was compared between the 2 arms using
the diary and by counting the amount of drug that
remained in its packaging. AEs were compared between
the two arms over the 6-cycle period with particular at-
tention to nausea or vomiting.
All analyses were performed using the SAS software,
version 9.1 (SAS Institute, Cary, NC).
Results
Assignment of patients and treatment compliance
From September 2005 to January 2008, 431 non meta-
static breast cancer patients were enrolled in 8 centres;
214 patients were randomly assigned to Cocculine (C)
and 217 to placebo (Figure 1). A total of 266 patients
(61.7%) were in the FAC/FEC stratum and 165 (38.3%)
in the TAC stratum. Major patient characteristics
at baseline are detailed in Table 2. The two arms
were well-balanced, with no statistically significant dif-
ferences between them. Median age was 52.8 years
(range 20–74); 237 patients (55.6%) were T1 a-b-c and
258 patients (60.6%) were pN+; and 35.3% of the
patients had susceptibility to nausea or vomiting. Treat-
ment compliance as estimated using patient diary and
tablet count was largely acceptable: according to the
diary, 71% of patients had taken the study drug per
protocol, and this figure was 81% according to the count
of remaining tablets (data not shown). Compliance was
similar between arms. A total of 263 patients (63.2%)
had taken standard anti-emetic treatment per protocol
during cycle 1. A total of 384 patients (90.8%) had
received chemotherapy for the entire study period but
146 patients (34.5%) had to delay CT (mainly due to
haematological toxicity) and 34 patients (8.0%) had at214 assigned to Cocculine group
213 received Cocculine as allocated 
1 received Placebo (dispensation mistake)
een September,2005 to 
ent randomisation
201 included in primary endpoint analysis per 
ITT
13 patients were non evaluable
13 questionnaires not received
Table 2 Patient characteristic
Patient characteristics Placebo Cocculine All patients p
Total 217 214 431
Age, years 0.56*
Median (min-max) 52.8 (20–74) 53.3 (30–74) 52.8 (20–74)
Delay from surgery (days)
Median (min-max) 27.50 (4.00–70.0) 27.0 (1.0–72.0) 27.0 (1.0–72.0) 0.90*
ECOG Performance Status n = 197 n = 198 n = 395 0.64†
0, n (%) 177 (89.8) 175 (88.4) 352 (89.1)
1, n (%) 20 (10.2) 23 (11.6) 43 (10.9)
Nausea and vomiting susceptibility n = 188 n = 189 n = 377 0.47†
Yes n (%) 63 (33.5) 70 (37.0) 133 (35.3)
pT grade n = 215 n = 211 n = 426 1.00††
T1 a-b-c, n(%) 119 (55.3) 118 (55.9) 237 (55.6)
T2, n(%) 87 (40.5) 85 (40.3) 172 (40.4)
T3, n(%) 7 (3.3) 7 (3.3) 14 (3.3)
T4, n(%) 2 (0.9) 1 (0.5) 3 (0.7)
pN grade n = 213 n = 213 n = 426 0.84†
N-, n(%) 85 (39.9) 83 (39.0) 168 (39.4)
N+, n(%) 128 (60.1) 130 (61.0) 258 (60.6)
*: Mann–Whitney U test; † : Person’s chi-square test; †† : Fischer test.
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number of delays and/or dose reductions was similar
between the two arms (data not shown). There was no
impact of Cocculine treatment on compliance to chemo-
therapy regimen. Of note, there was no statistical differ-
ence in the use of concomitant anti-emetic rescue
medication between the 2 study arms at any time during
the study period (data not shown).
CINV assessed by patients using FLIE scores [Table 3] or
daily diaries [Table 4]
In total, 403 of 431 patients (93.5%) were assessable
for the primary endpoint (FLIE nausea score during 1st
CT course): 28 patients were non evaluable, 15 in the
placebo and 13 in the Cocculine arms (Table 3). Non-
assessable patients were accounted for 7 who withdrew
consent, 17 from whom questionnaires were not
received, and 4 who returned questionnaires that were
not evaluable.
Using the FLIE questionnaire, nausea scores after the
1st chemotherapy cycle were 6.02 and 6.07 for placebo
and Cocculine arms, respectively (p = 0.84). A total
of 205 patients (50.9%; 103 patients in the placebo and
102 in the Cocculine arms) had scores > 6 indicative of
no impact of nausea on quality of life. FLIE analysis
results are reported in Table 3. There was no difference
between the 2 arms when analysis was performed by
chemotherapy stratum; and there was no difference in
the subgroup of patients with known susceptibility to
nausea and vomiting (Table 3).Nausea, vomiting and global emesis FLIE scores were
not statistically different at any time between the two
arms (data not shown).
Based on daily diaries, the intensity of nausea reported
by patients over the first 3 cycles of chemotherapy was
very low (median nausea severity: 1st cycle: 0.56 [P] vs.
0.58 [C], p = 0.61 [Table 4]; 2nd cycle: 0.52 [P] vs. 0.60
[C], p=0.36; and 3rd cycle: 0.93 [P] vs. 0.40 [C]; p=0.45,
data not shown) with no significant difference between
the two arms. Patient had few vomiting episodes of low
intensity (medians were 0 for the 3 cycles). More
patients reported vomiting episodes during the 3rd CT
course in the placebo (34.2%) than in the Cocculine
arms (23.4%), p = 0.03 (data not shown). However, these
observations were not maintained over the 4, 5 and 6th
cycles of CT and had no impact on FLIE vomiting score.CINV assessed by investigators (NCI –CTCAE V3.0 grading)
Based on investigators assessments using CTCAE
V3.0, nausea occurred in 51.1% versus 47.4% of the
patients treated with placebo and Cocculine respectively
(p = 0.48) during the 1st CT cycle (Table 5), in 42.3%
(P) versus 48.9% (C) (p = 0.21) during the 2nd CT cycle;
and in 43.2% (P) versus 45.8% (C) (p = 0.63) during the
3rd CT cycle (data not shown). No significant differences
were noted during cycles 4 to 6.
Frequency of vomiting was also similar between the 2
arms: 19.7% versus 21.1% (p = 0.72) for Placebo and
Cocculine respectively during the 1st CT cycle (Table 5);
Table 3 Impact of nausea on quality of life during cycle 1 of chemotherapy: nausea dimension of the FLIE score in ITT
population
Placebo Cocculine All patients p
All patients n=217 n=214 n=431
missing data** 15 13 28
number of patients evaluable 202 201 403
Quantitative 0.84*
Median nausea Score (Min-Max) 6.02 (1.11 – 7) 6.07 (1.22 – 7) 6.02 (1.11 – 7)
Mean ± sd 5.43 ± 1.57 5.45 ± 1.57 5.44 ± 1.57
Qualitative
Patients with no impact of nausea on daily life (i.e. a median score > 6), n (%) 103 (51.0) 102 (50.7) 205 (50.9) 0.96†
Stratum FAC-FEC n=135 n=131 n=266
missing data ** 9 7 16
number of patients evaluable 126 124 250
Quantitative
Median nausea score (min-max) 5.93 (1.11–7) 6.08 (1.65–7) 6.03 (1.11–7) 0.69*
Mean ± sd 5.37 (1.66) 5.48 (1.52) 5.42 (1.49)
Qualitative
Patients with no impact of nausea on daily life (i.e. mean score > 6), n (%) 63 (50.0) 63 (50.8) 126 (50.4) 0.90†
Stratum TAC n=82 n=83 n=165
missing data** 6 6 12
number of patients evaluable 76 77 153
Quantitative
Median nausea score (min-max) 6.07 (1.90-7) 6.02 (1.22-7)
Mean ± sd 5.54 (1.43) 5.39 (1.66) 5.47 (1.55)
Qualitative
Patients with no impact of nausea on daily life (i.e. mean score > 6), n (%) 40 (52.6) 39 (50.6) 79 (51.6) 0.81†
Patients with susceptibility to NV (Yes) n=61 n=66 n=127
missing data** 2 4 6
number of patients evaluable 59 62 121
Quantitative
Median nausea score (min-max) 5.85 (1.11–7) 5.81 (1.22–7) 5.83 (1.11–7) 0.36*
Mean ± sd 5.29 (1.66) 5.04 (1.71) 5.16 (1.69)
Qualitative
Patients with no impact of nausea on daily life (i.e. mean score > 6), n (%) 30 (49.2) 28 (42.4) 58 (45.7) 0.45†
*: Mann–Whitney U test †: Person’s chi-square test.
**: missing data i.e. number of patients with more than 5 missing items in the FLIE questionnaire.
n: number of patients.
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cycle; and 22.2 (P) versus 16.9% (C) (p = 0.22) during
the 3rd CT cycle (data not shown). The incidence of se-
vere nausea and vomiting (i.e. Grade ≥ 2) reported by
the investigators during the 1st CT cycle was also similar
between the 2 treatment groups (Table 5): severe nausea
occurred in 17.6% versus 15.7% of patients receiving Pla-
cebo versus Cocculine (p = 0.62) and severe vomiting in
10.8% versus 12.0% of patients receiving Placebo versus
Cocculine (p = 0.72).Four serious adverse events (SAEs), including 1 cuta-
neous papular eruption, 2 cases of anxiety/depression
syndrome and 1 cholecystectomy for biliary colic, were
reported but none were related to Cocculine. The overall
incidence of AE (any type any grade) was similar be-
tween the 2 arms.
Discussion
This study evaluates the potential clinical benefit of a
complex homeopathic medicine for the control of CINV
Table 4 Patient self -evaluation of nausea and vomiting














with at least 1 episode
of nausea, n (%)
164 (81.6) 155 (79.5) 319 (80.6)
Nausea severity 0.61*




Median (min-max) 0.56 (0–8.5) 0.58 (0–8.3) 0.56 (0–8.5)
Vomiting frequency 0.56†





with at least 1 episode
of vomiting, n (%)
51 (27.4) 42 (24.7) 93 (26.1)
Vomiting severity




Median (min-max) 0.00 (0–7.60) 0.00 (0–5.0) 0.00 (0–7.60)
*: Mann–Whitney U test †: Person’s chi-square test.
Table 5 Frequency of nausea and vomiting AEs during 1st cyc
Frequency of nausea and vomiting AE (all grade) during 1st cycle of ch
Missing data
Number of patients evaluable
Number of patient with at least 1 AE nausea (%)
Missing data
Number of patients evaluable
Number of patient with at least 1 AE vomiting, n (%)
Frequency of severe nausea and vomiting AE (Grade ≥ 2) during 1st cyc
Missing data
Number of patients evaluable, n
Number of patient with at least 1 severe nausea AE (i.e. Grade ≥2), n (%)
Missing data
Number of patients evaluable
Number of patient with at least 1 severe vomiting AE (i.e. Grade ≥ 2), n (%)
†Person’s chi-square test.
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breast cancer patients receiving uniform protocols of
chemotherapy. Overall, adding thiscomplex homeopathic
medicine to standard anti-emetic regimen did not im-
prove the control of CINV in early breast cancer
patients under chemotherapy regimen. FLIE nausea
scores after the first chemotherapy course were 6.02 and
6.07 for placebo and Cocculine arms, respectively (p =
0.84, Table 3).
Our study was initially performed to confirm the effi-
cacy of Cocculine in control of CINV in early breast
cancer patients as reported by Genre et al., [16]. How-
ever, our data showed no superiority of Cocculine over
placebo. Several aspects of methodology may explain
this discrepancy. Firstly, Genre et al. performed a small,
single-centre study whereas more than 400 patients were
enrolled in our multi-center clinical trial. Secondly, our
prospective investigation was based on the FLIE score
derived from a validated 18-item, patient-reported ques-
tionnaire. As CINV is frequently underestimated by
caregivers, the FLIE questionnaire is an essential and
better patient-reported tool to assess the functional im-
pact of CT on patients’ daily lives. Relevant to our nega-
tive results, it should be noted that in the current study
the percentage of patients with no or minimal impact of
CINV on their daily life was particularly high (51% of
patients in both placebo and Cocculine arms) and the
incidence of severe nausea and vomiting were low (nau-
sea: 17.6-15.7%, and vomiting 10.8-12%, Table 5). In con-
trast, Genre et al. have reported that 87.5% of patients
enrolled in placebo arm have experienced nausea epi-
sodes during the first cycle of chemotherapy [16]. Of
note, the emetyogenic properties of the chemotherapyle of chemotherapy
emotherapy
Placebo n = 217 CocculineW n = 214 All n = 431 p †
39 20 59
178 194 372
91 (51.1) 92 (47.4) 83 (49.2) 0.48
39 20 59
178 194 372
35 (19.7) 41 (21.1) 76 (20.4) 0.72
le of chemotherapy
Placebo n = 217 Cocculine n = 214 All n = 431 p †
47 29 76
170 185 355
30 (17.6) 29 (15.7) 59 (16.6) 0.62
41 22 63
176 192 368
19 (10.8) 23 (12.0) 42 (11.4) 0.72
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treatment were similar. For additional comparison, the
prevalence of CINV in previously reported clinical trials
was around 65% (depending on chemotherapy regimen,
and/or anti-emetic treatment used) [10,12,13]. Of note,
one limitation of our study is the absence of data collec-
tion related to patients' belief as to group allocation (Coc-
culine or placebo), patient’s belief of homeopathy efficacy,
comfort of homeopathy, pre-existing anxiety, history of
alcohol consumption. Therefore, no comparison between
groups for such patient-related factors, which may have
influenced the development of CINV, was performed.
Considering that patients’ expectancies are largely
influenced by the attention and information they
received from clinicians, and are predictors, and, likely,
contributing factors to the development of treatment-
related emesis [20,21], we have followed 34 breast cancer
patients during their 1st cycle of chemotherapy (FAC50,
FEC100 or TAC) in a post-study cohort. In contrast to
patients enrolled in our Phase III, these patients were
requested to complete a FLIE questionnaire without a
recall on Day 5. Interestingly, at the end of the 1st cycle,
the proportion of patients with no or minimal impact of
nausea on QoL (FLIE score >6) in this post-study cohort
was only 31% (data not shown) versus 51 % in our Phase
III population. Therefore, it is possible that extra atten-
tion provided to the patients enrolled in this study (i.e.
with 5-day recall) may have change their perception of
may be beneficial in terms of the occurrence and inten-
sity of treatment-related side effects [6,22].
Our study has evaluated the effect of a complex
homeopathic medicine in a large randomized study. This
strategy was chosen for the following reasons: (i) first of
all, the management of side effects related to conven-
tional treatment need to be integrated in the routine of
daily clinical practice thus not allowing time-consuming
individual homeopathic prescription, (ii) secondly, the
use of homeopathy with an individualized remedy is ex-
pensive and required the implication of the same experi-
enced homeopath that is difficult to set up in
multicenter trial and (iii) finally, individualized prescrip-
tion is not easily compatible with double-blind rando-
mized trials [23].
Although controversial, homeopathy is increasingly
used worldwide as a complementary medicine and has
been largely investigated in clinical trials [24-27]. How-
ever, no definitive conclusions can be drawn due to the
low methodological quality of clinical trials, the small
number of patients involved, lack of replication and pre-
sumed publication bias [28]. More and higher quality
clinical trials, unbiased by belief or disbelief in the prin-
ciples of homeopathy, need to be performed to assess
the potential effect of such alternative medicines in con-
trolling the side effects of cancer treatment [29].Conclusions
In conclusion, this double-blinded, placebo-controlled,
randomised Phase III study showed that adding a com-
plex homeopathic treatment to standard anti-emetic
prophylaxis does not improve the control of CINV in
early breast cancer patients.
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